BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.

Autor:	Jimenez-Sainz J; Department of Therapeutic Radiology, Yale University, New Haven, United States., Mathew J; Department of Therapeutic Radiology, Yale University, New Haven, United States., Moore G; Department of Therapeutic Radiology, Yale University, New Haven, United States., Lahiri S; Department of Therapeutic Radiology, Yale University, New Haven, United States., Garbarino J; Department of Therapeutic Radiology, Yale University, New Haven, United States., Eder JP; Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, United States., Rothenberg E; Department of Biochemistry and Molecular Pharmacology, New York University, New York, United States., Jensen RB; Department of Therapeutic Radiology, Yale University, New Haven, United States.
Jazyk:	angličtina
Zdroj:	ELife [Elife] 2022 Sep 13; Vol. 11. Date of Electronic Publication: 2022 Sep 13.
DOI:	10.7554/eLife.79183
Abstrakt:	Pathogenic mutations in the BRCA2 tumor suppressor gene predispose to breast, ovarian, pancreatic, prostate, and other cancers. BRCA2 maintains genome stability through homology-directed repair (HDR) of DNA double-strand breaks (DSBs) and replication fork protection. Nonsense or frameshift mutations leading to truncation of the BRCA2 protein are typically considered pathogenic; however, missense mutations resulting in single amino acid substitutions can be challenging to functionally interpret. The majority of missense mutations in BRCA2 have been classified as Variants of Uncertain Significance (VUS) with unknown functional consequences. In this study, we identified three BRCA2 VUS located within the BRC repeat region to determine their impact on canonical HDR and fork protection functions. We provide evidence that S1221P and T1980I, which map to conserved residues in the BRC2 and BRC7 repeats, compromise the cellular response to chemotherapeutics and ionizing radiation, and display deficits in fork protection. We further demonstrate biochemically that S1221P and T1980I disrupt RAD51 binding and diminish the ability of BRCA2 to stabilize RAD51-ssDNA complexes. The third variant, T1346I, located within the spacer region between BRC2 and BRC3 repeats, is fully functional. We conclude that T1346I is a benign allele, whereas S1221P and T1980I are hypomorphic disrupting the ability of BRCA2 to fully engage and stabilize RAD51 nucleoprotein filaments. Our results underscore the importance of correctly classifying BRCA2 VUS as pathogenic variants can impact both future cancer risk and guide therapy selection during cancer treatment. Competing Interests: JJ, JM, GM, SL, JG, JE, ER, RJ No competing interests declared (© 2022, Jimenez-Sainz et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu